Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. AQST
stocks logo

AQST

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
13.35M
+12.46%
-0.138
-27.48%
11.52M
+32.13%
-0.172
-28.33%
13.98M
+39.78%
-0.168
+20%
Estimates Revision
The market is revising Downward the revenue expectations for Aquestive Therapeutics, Inc. (AQST) for FY2025, with the revenue forecasts being adjusted by -0.25% over the past three months. During the same period, the stock price has changed by 18.82%.
Revenue Estimates for FY2025
Revise Downward
down Image
-0.25%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-0.17%
In Past 3 Month
Stock Price
Go Up
up Image
+18.82%
In Past 3 Month
Wall Street analysts forecast AQST stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AQST is 9.50 USD with a low forecast of 8.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast AQST stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AQST is 9.50 USD with a low forecast of 8.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.440
sliders
Low
8.00
Averages
9.50
High
12.00
Current: 6.440
sliders
Low
8.00
Averages
9.50
High
12.00
Piper Sandler
Overweight
maintain
$5 -> $8
2025-11-07
Reason
Piper Sandler
Price Target
$5 -> $8
2025-11-07
maintain
Overweight
Reason
Piper Sandler raised the firm's price target on Aquestive Therapeutics to $8 from $5 and keeps an Overweight rating on the shares after hosting a fireside chat with the company's senior leadership ahead of data presentations for Anaphylm at the upcoming American College of Allergy, Asthma and Immunology meeting. Key discussion topics included the body of data surrounding the product; the NDA review process; and commercial launch plans. Piper remains confident in a timely FDA approval of Anaphylm, and believes the product will be met with an enthusiastic prescriber audience.
Oppenheimer
Oppenheimer
Outperform
maintain
$7 -> $8
2025-09-08
Reason
Oppenheimer
Oppenheimer
Price Target
$7 -> $8
2025-09-08
maintain
Outperform
Reason
Oppenheimer raised the firm's price target on Aquestive Therapeutics to $8 from $7 and keeps an Outperform rating on the shares. The firm notes that last week, Aquestive announced that the FDA would not require an AdCom for its NDA of Anaphylm sending shares up +43.77% as investors interpret the update increasing the chances of approval. While Oppenheimer saw an AdCom as likely and increasing the path to approval given the established approval path with neffy and Analphylm's novel route of administration, it appears the data package submitted suffices in guiding the FDA on addressing key topics for potential approval without the need for expert recommendations.
LifeSci Capital
initiated
$10
2025-09-03
Reason
LifeSci Capital
Price Target
$10
2025-09-03
initiated
Reason
LifeSci Capital initiated coverage of Aquestive Therapeutics with an Outperform rating and $10 price target.
Oppenheimer
Oppenheimer
Outperform
to
Hold
downgrade
$15 -> $7
2025-06-02
Reason
Oppenheimer
Oppenheimer
Price Target
$15 -> $7
2025-06-02
downgrade
Outperform
to
Hold
Reason
Oppenheimer lowered the firm's price target on Aquestive Therapeutics to $7 from $15 and keeps an Outperform rating on the shares following quarterly results. With the Anaphylm NDA submitted on April 1, management expects an FDA response next month and a potential action date in late January/early February 2026. Preparations for a potential AdCom are ongoing. The firm is encouraged by ongoing commercialization efforts, including commercial team build-out, growing anaphylaxis awareness, and continuing payer engagements. Aquestive also plans to engage ex-U.S. regulators and pursue partnerships to strengthen its balance sheet, adds Oppenheimer.
Oppenheimer
Oppenheimer
Outperform
to
Underperform
downgrade
$15 -> $7
2025-06-02
Reason
Oppenheimer
Oppenheimer
Price Target
$15 -> $7
2025-06-02
downgrade
Outperform
to
Underperform
Reason
Oppenheimer assumed coverage of Aquestive Therapeutics with an Outperform rating with a price target of $7, down from $15, following quarterly results. With the Anaphylm NDA submitted on April 1, management expects an FDA response next month and a potential action date in late January/early February 2026. Preparations for a potential AdCom are ongoing. The firm is encouraged by ongoing commercialization efforts, including commercial team build-out, growing anaphylaxis awareness, and continuing payer engagements. Aquestive also plans to engage ex-U.S. regulators and pursue partnerships to strengthen its balance sheet, adds Oppenheimer.
Piper Sandler
Overweight
to
Overweight
downgrade
$8 -> $5
2025-05-13
Reason
Piper Sandler
Price Target
$8 -> $5
2025-05-13
downgrade
Overweight
to
Overweight
Reason
Piper Sandler lowered the firm's price target on Aquestive Therapeutics to $5 from $8 and keeps an Overweight rating on the shares.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Aquestive Therapeutics Inc (AQST.O) is -10.32, compared to its 5-year average forward P/E of -4.54. For a more detailed relative valuation and DCF analysis to assess Aquestive Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.54
Current PE
-10.32
Overvalued PE
-1.66
Undervalued PE
-7.42

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-6.53
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-2.86
Undervalued EV/EBITDA
-10.20

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
4.27
Current PS
0.00
Overvalued PS
7.32
Undervalued PS
1.22
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

AQST News & Events

Events Timeline

(ET)
2025-11-05
16:33:17
Aquestive Therapeutics lowers FY25 revenue forecast to $44M-$50M, down from $47M-$56M
select
2025-11-05
16:31:01
Aquestive Therapeutics announces Q3 earnings per share of 14 cents, surpassing consensus estimate of 11 cents.
select
2025-11-04 (ET)
2025-11-04
07:31:24
Aquestive names Davis as Chief Development Officer, Slatko as interim Chief Marketing Officer, and Boyd as Chief Product Officer.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
6.5
11-12Benzinga
Jim Cramer: Joby Is Experiencing Significant Financial Losses

  • Jim Cramer's Insights: On CNBC's "Mad Money Lightning Round," Jim Cramer described Aquestive Therapeutics as a "very interesting spec" and highlighted Amphenol Corporation as a strong stock, following its impressive fiscal third-quarter results.

  • Analyst Ratings: Piper Sandler analyst David Amsellem maintained an Overweight rating on Aquestive Therapeutics, raising its price target from $5 to $8, while Amphenol reported a 53% year-on-year sales increase to $6.19 billion.

  • Joby Aviation's Performance: Cramer criticized Joby Aviation for its significant losses, as the company reported a quarterly loss of 48 cents per share, which was worse than the expected loss of 19 cents.

  • Stock Movements: Following the earnings reports, Amphenol shares fell slightly by 0.3%, while Aquestive Therapeutics shares rose by 2%, and Joby Aviation shares increased by 3.7%.

[object Object]
Preview
6.5
11-12CNBC
Cramer's Lighting Round: "It's advisable to hold onto Amphenol"

  • Amphenol Stock Recommendation: Jim Cramer highlights Amphenol as a strong investment choice in the cable sector, suggesting it is a great stock to hold.

  • Aquestive Therapeutics Speculation: Cramer finds Aquestive Therapeutics to be an intriguing speculative investment opportunity.

  • Joby Aviation Concerns: Cramer expresses concerns about Joby Aviation, noting that the company is losing too much money.

  • Investment Resources: Viewers are encouraged to download Jim Cramer's Guide to Investing for free and to join the CNBC Investing Club for market insights.

[object Object]
Preview
7.0
11-06SeekingAlpha
Aquestive Provides Update on Q1 2026 Anaphylm Launch Preparedness and Revenue Forecast of $44M-$50M While Progressing Adrenaverse Platform

  • Management Insights: CEO Daniel Barber emphasized the growing awareness of the Anaphylm sublingual film among allergists, with a planned launch in Q1 2026 pending FDA approval. Leadership changes were announced to enhance R&D efforts and commercial readiness.

  • Financial Overview: The company reported Q3 2025 revenues of $12.8 million and a net loss of $15.4 million. Recent equity raises totaling $160 million are expected to support operations through 2027, with a reaffirmed revenue guidance of $44 million to $50 million for the year.

  • Regulatory and Market Strategy: The FDA review for Anaphylm is on track, with no advisory committee meeting planned. The company is also preparing for international regulatory filings in Canada and the EMA in early 2026, focusing on a targeted approach to allergists for the product launch.

  • Analyst Sentiment and Risks: Analysts expressed neutral to slightly positive sentiment regarding the company's readiness and market potential, while management acknowledged risks related to FDA review timing and competitive pressures, emphasizing their strategic preparations and differentiation in the market.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Aquestive Therapeutics Inc (AQST) stock price today?

The current price of AQST is 6.44 USD — it has increased 4.72 % in the last trading day.

arrow icon

What is Aquestive Therapeutics Inc (AQST)'s business?

Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. It has four commercialized products marketed by the Company’s licensees in the United States and around the world and is the manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, including PharmFilm, and has proven drug development and commercialization capabilities. The Company is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions. Its portfolio includes Anaphylm, AQST-108, Libervant, Suboxone, and Emylif.

arrow icon

What is the price predicton of AQST Stock?

Wall Street analysts forecast AQST stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AQST is 9.50 USD with a low forecast of 8.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Aquestive Therapeutics Inc (AQST)'s revenue for the last quarter?

Aquestive Therapeutics Inc revenue for the last quarter amounts to 12.81M USD, decreased -5.43 % YoY.

arrow icon

What is Aquestive Therapeutics Inc (AQST)'s earnings per share (EPS) for the last quarter?

Aquestive Therapeutics Inc. EPS for the last quarter amounts to -0.14 USD, increased 7.69 % YoY.

arrow icon

What changes have occurred in the market's expectations for Aquestive Therapeutics Inc (AQST)'s fundamentals?

The market is revising Downward the revenue expectations for Aquestive Therapeutics, Inc. (AQST) for FY2025, with the revenue forecasts being adjusted by -0.25% over the past three months. During the same period, the stock price has changed by 18.82%.
arrow icon

How many employees does Aquestive Therapeutics Inc (AQST). have?

Aquestive Therapeutics Inc (AQST) has 142 emplpoyees as of December 05 2025.

arrow icon

What is Aquestive Therapeutics Inc (AQST) market cap?

Today AQST has the market capitalization of 786.31M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free